Comment from Biostax Corp d/b/a Attune Biotech Inc.

Summary: Biostax Corp (Attune Biotech Inc.) submits a white paper supporting the FDA's initiative to modernize drug repurposing for unmet medical needs. They argue that low-dose naltrexone (LDN) is a prime candidate for this framework because it has established safety, widespread clinical use, and significant federal research support, but lacks a standardized, FDA-approved pharmaceutical product due to market failures.